142 related articles for article (PubMed ID: 17624636)
1. [Role of pharmacogenetics in chemotherapy of colorectal cancers].
Ceppa F; Fontan E; Cremades S; Bihannic R; Bousquet A; Beauvillain L; Burnat P
Rev Med Interne; 2007 Sep; 28(9):594-602. PubMed ID: 17624636
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
Tan BR; McLeod HL
Semin Oncol; 2005 Feb; 32(1):113-9. PubMed ID: 15726513
[TBL] [Abstract][Full Text] [Related]
3. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
Bhushan S; McLeod H; Walko CM
Clin Colorectal Cancer; 2009 Jan; 8(1):15-21. PubMed ID: 19203892
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy.
Di Francia R; Siesto RS; Valente D; Spart D; Berretta M
Eur Rev Med Pharmacol Sci; 2012 Sep; 16(9):1211-7. PubMed ID: 23047504
[TBL] [Abstract][Full Text] [Related]
5. [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Laurent-Puig P; Lièvre A; Ducreux M; Loriot MA
Bull Cancer; 2008 Oct; 95(10):935-42. PubMed ID: 19004723
[TBL] [Abstract][Full Text] [Related]
6. Effects of MTHFR genetic polymorphisms on toxicity and clinical response of irinotecan-based chemotherapy in patients with colorectal cancer.
Li P; Chen Q; Wang YD; Ha MW
Genet Test Mol Biomarkers; 2014 May; 18(5):313-22. PubMed ID: 24611457
[TBL] [Abstract][Full Text] [Related]
7. Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Toffoli G; Cecchin E
J Chemother; 2004 Nov; 16 Suppl 4():31-5. PubMed ID: 15688606
[TBL] [Abstract][Full Text] [Related]
8. [SNPs associated with adverse effects].
Isomura M; Miki Y
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1908-13. PubMed ID: 16282725
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
[TBL] [Abstract][Full Text] [Related]
10. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
Marcuello E; Altés A; Menoyo A; Rio ED; Baiget M
Cancer Chemother Pharmacol; 2006 Jun; 57(6):835-40. PubMed ID: 16187112
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of colorectal cancer.
Marsh S
Expert Opin Pharmacother; 2005 Dec; 6(15):2607-16. PubMed ID: 16316300
[TBL] [Abstract][Full Text] [Related]
12. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics in chemotherapy of colorectal cancer.
Henriette Tanja L; Guchelaar HJ; Gelderblom H
Best Pract Res Clin Gastroenterol; 2009; 23(2):257-73. PubMed ID: 19414151
[TBL] [Abstract][Full Text] [Related]
14. Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.
Budai B; Komlósi V; Adleff V; Pap É; Réti A; Nagy T; Kralovánszky J; Láng I; Hitre E
Pharmacogenet Genomics; 2012 Jan; 22(1):69-72. PubMed ID: 22044939
[TBL] [Abstract][Full Text] [Related]
15. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacogenetics and tumor sensitivity of antineoplastic agents. Application to colorectal cancer].
Milano G
Rev Prat; 2008 May; 58(10):1056-9. PubMed ID: 18652401
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer.
Moradi-Marjaneh R; Khazaei M; Seifi S; Hassanian SM; Ferns GA; Avan A
Curr Pharm Des; 2018; 24(23):2710-2718. PubMed ID: 30051785
[TBL] [Abstract][Full Text] [Related]
18. Tailoring chemotherapy in advanced colorectal cancer.
Park DJ; Stoehlmacher J; Lenz HJ
Curr Opin Pharmacol; 2003 Aug; 3(4):378-85. PubMed ID: 12901946
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
Cortejoso L; López-Fernández LA
Pharmacogenomics; 2012 Jul; 13(10):1173-91. PubMed ID: 22909207
[TBL] [Abstract][Full Text] [Related]
20. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
